Posaconazole
Specifications
171228-49-2CAS Number
682-747-8EC Number
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-oneIUPAC Name
C37H42F2N8O4Chemical Formula
700.8 g/molMolecular Weight
Posaconazole; 171228-49-2; Noxafil; Sch 56592; SCH-56592; SCH56592; posaconazol; Schering 56592; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; DTXSID6049066; (-)-POSACONAZOLE; 6TK1G07BHZ; CHEBI:64355; DTXCID401474254; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; posaconazolum; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((2S,3S)-2-hydroxypentan-3-yl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)piperazin-1-yl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-(4-(4-(4-(((3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-1,2,4-triazol-3-one; RefChem:56731; Posaconazole Delayed-Release; NOXAFIL POWDERMIX KIT; J02AC04; 4-(4-(4-(4-(((5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-4,5-dihydro-1H-1,2,4-triazol-5-one; Posaconazole SP; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE; MFCD00941162; C37H42F2N8O4; CHEMBL1397; MMV688774; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one; POS; CAS-171228-49-2; UNII-6TK1G07BHZ; pasaconazole; Posanol; Spriafil; Posaconazole?; Posaconazole [USAN:INN:BAN]; HSDB 7421; NCGC00185736-01; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3R-[3alpha(1S*,2S*),5alpha]]-; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-; Noxafil; Posaconazole; Sch 56592; Noxafil (TN); Posaconazole - Form I; Posaconazole (Standard); Posaconazole - Form III; POSACONAZOLE [MI]; POSACONAZOLE [INN]; POSACONAZOLE [JAN]; POSACONAZOLE [HSDB]; POSACONAZOLE [USAN]; POSACONAZOLE [VANDF]; POSACONAZOLE [MART.]; 177571-33-4; POSACONAZOLE [WHO-DD]; SCHEMBL991747; orb1300976; orb3141223; Posaconazole (JAN/USAN/INN); POSACONAZOLE [EMA EPAR]; SCHEMBL29372531; GTPL11428; Posaconazole - Bio-X trade mark; POSACONAZOLE [GREEN BOOK]; GLXC-05188; POSACONAZOLE [ORANGE BOOK]; Tox21_113620; BDBM50181473; EBC-11286; HY-17373R; MSK156847; s1257; AKOS005145917; Tox21_113620_1; AC-1350; CCG-270387; CS-0998; DB01263; FP27107; KS-1413; NCGC00274060-01; NCGC00274060-02; NCGC00274060-07; 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one; BP163592; BP163593; BP164281; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)- 4-((4-(4-(4-(1-((1S,2S)-1-ety; HY-17373; Posaconazole in combination with MGCD290; SY107631; NS00002082; P2477; SW219391-1; T6211; D02555; SBI-0654141.0001; AB01274762-01; AB01274762_02; Posaconazole, VETRANAL(TM), analytical standard; EN300-19769273; Q906453; BRD-K06222852-001-03-2; BRD-K06222852-001-05-7; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S ,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-tria zol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2 ,4-triazol-1-yl)-D-threo-pentitol; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-2-((2S,3S)-2-HYDROXYPENTAN-3-YL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE; 4-(4-(4-(4-(((5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-[4-(4-{4-[(R)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1S,2S)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-( 1H-1,2,4-triazol-1-yl)-?; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-; PCZ; Posaconazole MicronizedSynonyms
Products Containing Posaconazole
녹사필장용정100밀리그램(포사코나졸(미분화))녹사필현탁액(포사코나졸(미분화))POSACONAZOL VIVANTA 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL TILLOMED 40 MG/ML SUSPENSION ORAL EFGPOSACONAZOL TARBIS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFGPOSACONAZOL TARBIS 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL FRESENIUS KABI 100 MG COMPRIMIDOS GASTRORRESISTENTESPOSACONAZOL AUROVITAS 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL ALTAN 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFGPOSACONAZOL ALMOVAR 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL AHCL 40 MG/ML SUSPENSION ORAL EFGPOSACONAZOL ACCORD 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFG
Page 1 of 7
Companies Selling Posaconazole
DR
Dr. Reddy's LaboratoriesIndiaML
MSN LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.ChinaTC
Tianjin Chempharmatech.Co.,Ltd.ChinaPage 1 of 6